ERBB2 and gastric cancer: Additionally, more than 50 such analyses in oncology have been published, including a study comparing trastuzumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced HER2-positive GC using data from the phase 3 ToGA (Trastuzumab for Gastric Cancer) trial [21].